Trials / Not Yet Recruiting
Not Yet RecruitingNCT07324850
A Study of SGB-7342 in Subjects With Obesity or Overweight
A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-7342 in Subjects With Obesity or Overweight
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Suzhou Sanegene Bio Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGB-7342 | SC injection, single dose |
| DRUG | SGB-7342-Matching placebo | Normal saline (0.9% NaCl) in a matching volume, SC injection, single dose |
Timeline
- Start date
- 2026-01-12
- Primary completion
- 2026-10-28
- Completion
- 2027-04-14
- First posted
- 2026-01-08
- Last updated
- 2026-01-09
Source: ClinicalTrials.gov record NCT07324850. Inclusion in this directory is not an endorsement.